BioSpace News Archive

MediPines is pleased to announce that their AGM100 device has been awarded the prestigious Silver Award for Testing and Diagnostic Products in the 2021 Medical Design Excellence Awards.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 11:30 a.m. ET.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate overview and participate in one-on-one investor meetings at the Goldman Sachs 42 nd Annual Global Healthcare Conference taking place virtually from June 8-11, 2021.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has entered into a collaboration agreement with MediSynergics, LLC.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020 Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020 Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020 Q1 2021

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1 at 2:00 pm EST

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical milestones Merger expected to be completed in third quarter of 2021; combined company expected to be listed on Nasdaq under the ticker “EFTR”

Advanced Human Imaging Limited is pleased to announce the Derma AI embedded in the AHI DermaScan has received CE Mark clearance in the European Union for the dermatology AI component in CompleteScan.